Orphan drug grants
FDA will award about 15 grants ranging from $20,000 to $100,000 in direct costs for up to three years to support clinical trials, according to an announcement in the Oct. 26 edition of the Federal Register. While some preliminary clinical research should already be available, the agency will consider drugs for which "persuasive pharmacologic evidence is available that a product has a reasonable possibility of being effective even though no clinical trials have been performed." Applications, which should be "for one discrete clinical trial," must be received by Jan. 25, 1988, with the earliest beginning date for awards July 1.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.